-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Nurix Therapeutics (NRIX) Scheduled to Post Quarterly Earnings on Friday
Nurix Therapeutics (NRIX) Scheduled to Post Quarterly Earnings on Friday
Nurix Therapeutics (NASDAQ:NRIX – Get Rating) is scheduled to be posting its quarterly earnings results on Friday, January 27th.
Nurix Therapeutics Stock Down 2.9 %
NASDAQ NRIX traded down $0.36 during mid-day trading on Thursday, hitting $12.10. The stock had a trading volume of 168,566 shares, compared to its average volume of 302,557. Nurix Therapeutics has a 52-week low of $7.52 and a 52-week high of $20.20. The company has a market cap of $570.49 million, a price-to-earnings ratio of -3.22 and a beta of 1.63. The company has a 50 day simple moving average of $11.70 and a 200 day simple moving average of $13.60.
Get Nurix Therapeutics alerts:Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the company. SVB Leerink lowered their target price on Nurix Therapeutics from $37.00 to $28.00 and set an "outperform" rating on the stock in a report on Tuesday, December 13th. HC Wainwright lowered their target price on Nurix Therapeutics to $53.00 in a report on Thursday, October 13th. Finally, Morgan Stanley assumed coverage on Nurix Therapeutics in a report on Tuesday, October 11th. They set an "equal weight" rating and a $11.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.90.
Institutional Investors Weigh In On Nurix Therapeutics
Hedge funds have recently made changes to their positions in the business. BlackRock Inc. raised its position in shares of Nurix Therapeutics by 11.0% in the 3rd quarter. BlackRock Inc. now owns 3,723,090 shares of the company's stock worth $48,512,000 after buying an additional 367,743 shares during the period. State Street Corp raised its position in shares of Nurix Therapeutics by 9.2% in the 3rd quarter. State Street Corp now owns 2,312,224 shares of the company's stock worth $30,128,000 after buying an additional 195,453 shares during the period. Vanguard Group Inc. raised its position in shares of Nurix Therapeutics by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,160,866 shares of the company's stock worth $28,156,000 after buying an additional 49,370 shares during the period. FMR LLC raised its position in shares of Nurix Therapeutics by 59.6% in the 2nd quarter. FMR LLC now owns 1,790,655 shares of the company's stock worth $22,688,000 after buying an additional 668,632 shares during the period. Finally, Wasatch Advisors Inc. raised its position in shares of Nurix Therapeutics by 28.5% in the 1st quarter. Wasatch Advisors Inc. now owns 1,546,689 shares of the company's stock worth $21,669,000 after buying an additional 343,100 shares during the period. Institutional investors and hedge funds own 91.33% of the company's stock.Nurix Therapeutics Company Profile
(Get Rating)
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
Further Reading
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- Mullen Automotive: The Good News, The Bad And The Ugly Outlook
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
纽瑞克斯治疗公司(纳斯达克代码:NRIX-GET Rating)定于1月27日(星期五)公布季度收益结果。
Nurix Treateutics股价下跌2.9%
周四午盘,纳斯达克NRIX股价下跌0.36美元,至12.10美元。该股成交量为168,566股,而其平均成交量为302,557股。Nurix Treateutics的52周低点为7.52美元,52周高位为20.20美元。该公司市值为5.7049亿美元,市盈率为-3.22倍,贝塔系数为1.63。该公司的50日简单移动均线切入位在11.70美元,200日简单移动均线切入位在13.60美元。
到达纽瑞克斯治疗公司警报:华尔街分析师预测经济增长
许多股票研究分析师对该公司发表了评论。SVB Leerink在12月13日(星期二)的一份报告中将Nurix Treateutics的目标价从37.00美元下调至28.00美元,并对该股设定了“跑赢大盘”的评级。在10月13日星期四的一份报告中,HC Wainwright将他们对Nurix Treeutics的目标价下调至53.00美元。最后,摩根士丹利在10月11日星期二的一份报告中承担了对Nurix治疗公司的报道。他们为该股设定了“同等权重”的评级和11.00美元的目标价。一名投资分析师对该股的评级为持有,七名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据,该公司目前的共识评级为“适度买入”,共识目标价为32.9美元。
机构投资者看好Nurix治疗公司
对冲基金最近对其在该业务中的头寸进行了调整。贝莱德股份有限公司在第三季度将其在纽力克斯治疗公司的股票持仓量提高了11.0%。贝莱德股份有限公司在此期间增持了367,743股,目前持有该公司3,723,090股股票,价值48,512,000美元。道富集团在第三季度将其在Nurix Treateutics的股票头寸提高了9.2%。道富银行目前持有该公司2,312,224股股票,价值30,128,000美元,在此期间又购买了195,453股。先锋集团(Vanguard Group Inc.)在第三季度将其在Nurix Treateutics的股票头寸提高了2.3%。先锋集团现在持有2,160,866股该公司股票,价值28,156,000美元,在此期间又购买了49,370股。FMR LLC在第二季度将其在Nurix Treateutics的股票头寸增加了59.6%。FMR LLC现在拥有1,790,655股该公司的股票,价值22,688,000美元,在此期间又购买了668,632股。最后,Wasatch Advisors Inc.在第一季度将其在Nurix Treateutics的股票头寸提高了28.5%。Wasatch Advisors Inc.现在持有1,546,689股该公司股票,价值21,669,000美元,在此期间又购买了343,100股。机构投资者和对冲基金持有该公司91.33%的股票。纽瑞克斯治疗公司简介
(获取评级)
Nurix治疗公司是一家生物制药公司,专注于治疗癌症和免疫疾病的小分子疗法的发现、开发和商业化。该公司开发了用于治疗复发或难治性B细胞恶性肿瘤的口服布鲁顿酪氨酸激酶(BTK)降解剂NX-2127;用于治疗复发或难治性B细胞恶性肿瘤和自身免疫性疾病的口服生物可用BTK降解剂NX-5948;以及口服可用于免疫肿瘤学适应症的Casitas B细胞性淋巴瘤原癌基因B(CBL-B)抑制剂NX-1607。
进一步阅读
- 免费获取StockNews.com关于Nurix治疗的研究报告(NRIX)
- 电子商务的未来:分析和新数据
- 雪佛龙以750亿美元的股票回购取悦股东
- 列维·施特劳斯非常适合收益型投资者
- 3只小盘股有很大的上涨空间
- 马伦汽车:好消息、坏消息和丑陋的前景
接受《Nurix治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Nurix Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧